Vanillic acid

Name: Vanillic acid
Brand: MedChemExpress
SKU: HY-N0708
Rating: 4.5 (1 reviews)

Cat. No.: HY-N0708 Purity: 99.43%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Vanillic acid is a flavoring agent found in edible plants and fruits, also found in Angelica sinensis. Vanillic acid inhibits NF-κB activation. Anti-inflammatory, antibacterial, and chemopreventive effects.

For research use only. We do not sell to patients.

Vanillic acid Chemical Structure

CAS No. : 121-34-6

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 85	In-stock	Estimated Time of Arrival: December 31
1 g	USD 110	In-stock	Estimated Time of Arrival: December 31
5 g		Get quote
10 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Vanillic acid:

Vanillic acid-¹³C₆ Get quote
Vanillic acid (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

p65

Microbial Metabolite

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 100 μg/mL Compound: 5	Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26995526]
A549	IC₅₀	> 100 μM Compound: 16	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
A549	IC₅₀	> 1000 μM Compound: 1b	Anticancer activity against human A549 cells after 24 hrs by MTT assay Anticancer activity against human A549 cells after 24 hrs by MTT assay	[PMID: 20466556]
A549	IC₅₀	> 30 μM Compound: 20	Anticancer activity against human A549 cells by SRB assay Anticancer activity against human A549 cells by SRB assay	[PMID: 21420296]
B16-F10	IC₅₀	> 1000 μM Compound: 1b	Anticancer activity against mouse B16F10 cells after 24 hrs by MTT assay Anticancer activity against mouse B16F10 cells after 24 hrs by MTT assay	[PMID: 20466556]
Hs 683	IC₅₀	> 1000 μM Compound: 1b	Anticancer activity against human Hs683 cells after 24 hrs by MTT assay Anticancer activity against human Hs683 cells after 24 hrs by MTT assay	[PMID: 20466556]
HT-22	EC₅₀	27.8 μM Compound: 36	Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay	[PMID: 32991171]
HT-29	IC₅₀	> 100 μg/mL Compound: 5	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26995526]
HUVEC	IC₅₀	> 100 μg/mL Compound: 5	Antiproliferative activity against human HUVEC cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human HUVEC cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26995526]
LoVo	IC₅₀	> 1000 μM Compound: 1b	Anticancer activity against human LoVo cells after 24 hrs by MTT assay Anticancer activity against human LoVo cells after 24 hrs by MTT assay	[PMID: 20466556]
LoVo	IC₅₀	91 μM Compound: 16	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
MCF7	IC₅₀	> 100 μg/mL Compound: 5	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26995526]
MCF7	IC₅₀	> 1000 μM Compound: 1b	Anticancer activity against human MCF7 cells after 24 hrs by MTT assay Anticancer activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 20466556]
OE33	IC₅₀	> 1000 μM Compound: 1b	Anticancer activity against human OE33 cells after 24 hrs by MTT assay Anticancer activity against human OE33 cells after 24 hrs by MTT assay	[PMID: 20466556]
PC-3	IC₅₀	> 100 μM Compound: 16	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
PC-3	IC₅₀	> 1000 μM Compound: 1b	Anticancer activity against human PC3 cells after 24 hrs by MTT assay Anticancer activity against human PC3 cells after 24 hrs by MTT assay	[PMID: 20466556]
RAW264.7	IC₅₀	23.2 μM Compound: 9	Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay	[PMID: 25666824]
SK-MEL-2	IC₅₀	> 30 μM Compound: 20	Anticancer activity against human SK-MEL-2 cells by SRB assay Anticancer activity against human SK-MEL-2 cells by SRB assay	[PMID: 21420296]
SK-MEL-28	IC₅₀	> 100 μM Compound: 16	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
SK-OV-3	IC₅₀	> 30 μM Compound: 20	Anticancer activity against human SKOV3 cells by SRB assay Anticancer activity against human SKOV3 cells by SRB assay	[PMID: 21420296]
T98G	IC₅₀	> 1000 μM Compound: 1b	Anticancer activity against human T98G cells after 24 hrs by MTT assay Anticancer activity against human T98G cells after 24 hrs by MTT assay	[PMID: 20466556]
U-373MG ATCC	IC₅₀	> 100 μM Compound: 16	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]
U-373MG ATCC	IC₅₀	> 1000 μM Compound: 1b	Anticancer activity against human U373 cells after 24 hrs by MTT assay Anticancer activity against human U373 cells after 24 hrs by MTT assay	[PMID: 20466556]
XF498	IC₅₀	> 30 μM Compound: 20	Anticancer activity against human XF498 cells by SRB assay Anticancer activity against human XF498 cells by SRB assay	[PMID: 21420296]

In Vitro

Vanillic acid is non-toxic to HT22 cells at all three concentrations (50, 100 and 200 μM); Vanillic acid co-treatment with Aβ_1-42 significantly increases (1.5-, 1.9- and 2-fold respectively) cell viability^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	HT22 cells
Concentration:	50, 100 and 200 μM
Incubation Time:	24 hours
Result:	Increased the viability of HT22 cells after 24 h at three different concentrations (50, 100 and 200 μM).

In Vivo

Vanillic acid (3-30 mg/kg; i.p.; 5 hours) inhibits Carrageenan-induced mechanical hyperalgesia, paw edema, and neutrophil and macrophage recruitment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss mice (25-30 g)^[1]
Dosage:	3, 10, or 30 mg/kg
Administration:	Intraperitoneal treatment; 5 hours
Result:	Inhibited Carrageenan-induced mechanical hyperalgesia, paw edema, and neutrophil and macrophage recruitment.

Molecular Weight

168.15

Formula

C₈H₈O₄

CAS No.

121-34-6

Appearance

Solid

Color

White to yellow

SMILES

O=C(O)C1=CC=C(O)C(OC)=C1

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Microorganisms

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (594.71 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.9471 mL	29.7354 mL	59.4707 mL
5 mM	1.1894 mL	5.9471 mL	11.8941 mL
10 mM	0.5947 mL	2.9735 mL	5.9471 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (14.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.75%

Select Batch:

Data Sheet (274 KB) SDS (393 KB)

COA (248 KB) HNMR (120 KB) RP-HPLC (182 KB)

Handling Instructions (2659 KB)

References

[1]. Calixto-Campos C, et al. Vanillic acid Inhibits Inflammatory Pain by Inhibiting Neutrophil Recruitment, Oxidative Stress, Cytokine Production, and NFκB Activation in Mice. J Nat Prod. 2015 Aug 28;78(8):1799-808. [Content Brief]

[2]. Amin FU, et al. Vanillic acid attenuates Aβ_1-42-induced oxidative stress and cognitive impairment in mice. Sci Rep. 2017 Jan 18;7:40753. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.9471 mL	29.7354 mL	59.4707 mL	148.6768 mL
	5 mM	1.1894 mL	5.9471 mL	11.8941 mL	29.7354 mL
	10 mM	0.5947 mL	2.9735 mL	5.9471 mL	14.8677 mL
	15 mM	0.3965 mL	1.9824 mL	3.9647 mL	9.9118 mL
	20 mM	0.2974 mL	1.4868 mL	2.9735 mL	7.4338 mL
	25 mM	0.2379 mL	1.1894 mL	2.3788 mL	5.9471 mL
	30 mM	0.1982 mL	0.9912 mL	1.9824 mL	4.9559 mL
	40 mM	0.1487 mL	0.7434 mL	1.4868 mL	3.7169 mL
	50 mM	0.1189 mL	0.5947 mL	1.1894 mL	2.9735 mL
	60 mM	0.0991 mL	0.4956 mL	0.9912 mL	2.4779 mL
	80 mM	0.0743 mL	0.3717 mL	0.7434 mL	1.8585 mL
	100 mM	0.0595 mL	0.2974 mL	0.5947 mL	1.4868 mL

Vanillic acid Related Classifications

Inflammation/Immunology Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vanillic acid121-34-6NF-κBBacterialEndogenous MetaboliteNuclear factor-κBNuclear factor-kappaBInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Vanillic acid

Customer Review

Other Forms of Vanillic acid:

Vanillic acid Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Vanillic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Vanillic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report